Pharma Aids Limited announcements
270 Dhaka Stock Exchange announcements for Pharma Aids Limited (PHARMAID) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (16).
- Credit Rating Result
National Credit Ratings Limited (NCR) has assigned the rating of the Company as "A" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements as on June 30, 2025.
- Emphasis of Matter
The auditor of the company has given the Emphasis of Matters paragraph in the audited financial statement for the year ended on 30 June 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Pharma%20Aids%20Limited_2025.pdf
- Resumption after Record Date
Trading of the shares of the company will resume on 08.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 07.12.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 03.12.2025 to 04.12.2025 and trading of the shares will remain suspended on record date i.e., 07.12.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 6.81 for July-September 2025 as against Tk. 5.66 for July-September 2024. NOCFPS was Tk. 8.87 for July-September 2025 as against Tk. 0.43 for July-September 2024. NAV per share was Tk. 145.32 as on September 30, 2025 and Tk. 138.58 as on June 30, 2025. (cont.) (Cont. News of PHARMAID): Reasons for deviation: EPS has increased compared to the 1st quarter of the previous year due to increase in sales. NOCFPS has increased due to increase in collection. NAVPS has increased due to increase in retained earnings. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 15, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration
The Board of Directors has recommended a 30% Cash Dividend for the year ended June 30, 2025. Date of AGM: 24.12.2025, Time: 11:30 AM, Venue: Digital Platform. Record Date: 07.12.2025. The Company has also reported an EPS of Tk. 20.45, NAV per share of Tk. 138.58, and NOCFPS of Tk. 12.74 for the year ended June 30, 2025, as against an EPS of Tk. 19.61, NAV per share of Tk. 109.89, and NOCFPS of Tk. 7.30 for the year ended June 30, 2024. (cont.) (cont. news of PHARMAID): Remarks: The 30% Cash Dividend is recommended keeping in mind the necessity of funds for land acquisition and the upcoming BMRE project. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (09.11.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 06, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 4.45 for January-March 2025 as against Tk. 7.46 for January-March 2024; EPS was Tk. 15.77 for July 2024-March 2025 as against Tk. 18.37 for July 2023-March 2024. NOCFPS was Tk. 5.58 for July 2024-March 2025 as against Tk. 12.81 for July 2023-March 2024. NAV per share was Tk. 133.93 as on March 31, 2025 and Tk. 109.89 as on June 30, 2024. Decrease in NOCFPS is due to increase in suppliers payment and financial expenses.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 5.66 for October-December 2024 as against Tk. 7.21 for October-December 2023; EPS was Tk. 11.32 for July-December 2024 as against Tk. 10.90 for July-December 2023. NOCFPS was Tk. 4.93 for July-December 2024 as against Tk. 10.17 for July-December 2023. NAV per share was Tk. 129.50 as on December 31, 2024 and Tk. 109.89 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Credit Rating Result
National Credit Ratings Limited (NCR) has assigned rating of the Company as "A" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements as on June 30, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.